Reply to: “ALT to qHBsAg ratio predicts HBsAg seroclearance in HBeAg-negative hepatitis B patients with Peg-IFNα based therapy”

IF 26.8 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Journal of Hepatology Pub Date : 2024-12-24 DOI:10.1016/j.jhep.2024.12.036

Rex Wan-Hin Hui, Lung-Yi Mak, Man-Fung Yuen

{"title":"Reply to: “ALT to qHBsAg ratio predicts HBsAg seroclearance in HBeAg-negative hepatitis B patients with Peg-IFNα based therapy”","authors":"Rex Wan-Hin Hui, Lung-Yi Mak, Man-Fung Yuen","doi":"10.1016/j.jhep.2024.12.036","DOIUrl":null,"url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>AUTHOR CONTRIBUTIONS</h2>RWH Hui was involved in manuscript design and drafting of manuscript. LY Mak was involved in critical revision of manuscript. MF Yuen was involved in critical revision of manuscript and overall study supervision. The authors declare that they have participated in the preparation of the manuscript and have seen and approved the final version.</section></section><section><section><h2>DATA AVAILABILITY STATEMENT</h2>The data from this study is available from the corresponding author upon reasonable request.</section></section><section><section><h2>Funding</h2>Innovative Research Fund of the State Key Laboratory of Liver Research, The University of Hong Kong (ref. no.: SKLLR/IRF/2018/07) and the S. K. Yee Medical Foundation Grant (ref. no.: 2141213). The funders had no involvement in study design, data collection/ analysis/ interpretation, writing of the manuscript or decision to submit the article for publication.</section></section><section><section><h2>Declaration of Competing Interest</h2>MF Yuen is an advisory board member and/or received research funding from AbbVie, Arbutus Biopharma, Assembly Biosciences, Bristol Myer Squibb, Dicerna Pharmaceuticals, GlaxoSmithKline, Gilead Sciences, Janssen, Merck Sharp and Dohme, Clear B Therapeutics, Springbank Pharmaceuticals; and received research funding from Arrowhead Pharmaceuticals, Fujirebio Incorporation and Sysmex Corporation. The remaining authors have no conflict of interests.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"11 1","pages":""},"PeriodicalIF":26.8000,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jhep.2024.12.036","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Section snippets

AUTHOR CONTRIBUTIONS

RWH Hui was involved in manuscript design and drafting of manuscript. LY Mak was involved in critical revision of manuscript. MF Yuen was involved in critical revision of manuscript and overall study supervision. The authors declare that they have participated in the preparation of the manuscript and have seen and approved the final version.

DATA AVAILABILITY STATEMENT

The data from this study is available from the corresponding author upon reasonable request.

Funding

Innovative Research Fund of the State Key Laboratory of Liver Research, The University of Hong Kong (ref. no.: SKLLR/IRF/2018/07) and the S. K. Yee Medical Foundation Grant (ref. no.: 2141213). The funders had no involvement in study design, data collection/ analysis/ interpretation, writing of the manuscript or decision to submit the article for publication.

Declaration of Competing Interest

MF Yuen is an advisory board member and/or received research funding from AbbVie, Arbutus Biopharma, Assembly Biosciences, Bristol Myer Squibb, Dicerna Pharmaceuticals, GlaxoSmithKline, Gilead Sciences, Janssen, Merck Sharp and Dohme, Clear B Therapeutics, Springbank Pharmaceuticals; and received research funding from Arrowhead Pharmaceuticals, Fujirebio Incorporation and Sysmex Corporation. The remaining authors have no conflict of interests.

查看原文本刊更多论文

回复：“ALT / qHBsAg比值预测hbeag阴性乙型肝炎患者接受Peg-IFNα治疗后的HBsAg清除率”

章节摘要作者投稿许秀华参与了稿件的设计和起草。LY Mak参与了手稿的关键性修改。袁教授参与了论文的关键性修改和整个研究的监督。作者声明，他们已经参与了稿件的准备，并已经看到并批准了最终版本。数据可用性声明本研究的数据可根据通讯作者的合理要求提供。香港大学肝脏研究国家重点实验室创新研究基金： SKLLR/IRF/2018/07)及余绍权医学基金资助(参考编号：: 2141213)。资助者不参与研究设计、数据收集/分析/解释、撰写论文或决定是否发表论文。袁国强是顾问委员会成员和/或获得了来自AbbVie， Arbutus Biopharma, Assembly Biosciences, Bristol Myer Squibb, Dicerna Pharmaceuticals, GlaxoSmithKline, Gilead Sciences, Janssen，默克夏普和Dohme， Clear B Therapeutics， Springbank Pharmaceuticals的研究资金；并获得了箭头制药公司、Fujirebio公司和Sysmex公司的研究资助。其余作者没有利益冲突。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Hepatology 医学-胃肠肝病学

CiteScore

46.10

自引率

4.30%

发文量

2325

审稿时长

30 days

期刊介绍： The Journal of Hepatology is the official publication of the European Association for the Study of the Liver (EASL). It is dedicated to presenting clinical and basic research in the field of hepatology through original papers, reviews, case reports, and letters to the Editor. The Journal is published in English and may consider supplements that pass an editorial review.